ReviewThe Journal of clinical investigation2006
T cell control in autoimmune bullous skin disorders.
Review in The Journal of clinical investigation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 215 citations in OpenAlex.
- Interventions for pemphigus vulgaris and pemphigus foliaceus.The Cochrane database of systematic reviews · 2009Pooled it
- FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus.Frontiers in immunology · 2022Trial
- T cell participation in autoreactivity to NC16a epitopes in bullous pemphigoid.Clinical and experimental immunology · 2015Trial
- Decoding autoimmune disease with single-cell immune repertoire and transcriptome sequencing: mechanisms and therapeutic opportunities.Frontiers in immunology · 2026Review
- Dihydroartemisinin attenuates pemphigus vulgaris by regulating Dsg3 and the TLR9/NF-κB pathway.American journal of translational research · 2026Article
- Bullous pemphigoid associated with vildagliptin in an elderly adult with diabetes mellitus. First case in Peru.Revista peruana de medicina experimental y salud publica · 2025Article
- The crosstalk between probiotics and T cell immunity.Frontiers in immunology · 2025Review
- HLA-Cw6 Polymorphism in Autoimmune Blistering Diseases.Biomolecules · 2024Article
- A Comprehensive Review on the Intricate Interplay between COVID-19 Immunization and the New Onset of Pemphigus Foliaceus.Vaccines · 2024Review
- New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review.Vaccines · 2024Review
- Oral mucosal lesions in the mouth as first sign of dermatological diseases and disorders.GMS hygiene and infection control · 2024Article
- Role of Human Leukocyte Antigen Class II in Antibody-Mediated Skin Disorders.Medicina (Kaunas, Lithuania) · 2023Review
- Skin-infiltrating T cells display distinct inflammatory signatures in lichen planus, bullous pemphigoid and pemphigus vulgaris.Frontiers in immunology · 2023Article
- HLA class II antigens in Croatian patients with pemphigus vulgaris and their correlation with anti-desmoglein antibodies.Frontiers in immunology · 2023Article
- The cytokine milieu of bullous pemphigoid: Current and novel therapeutic targets.Frontiers in medicine · 2023Review
- Expression of the Selected Proteins of JAK/STAT Signaling Pathway in Diseases with Oral Mucosa Involvement.International journal of molecular sciences · 2022Article
- Association of specific HLA alleles and haplotypes with pemphigus vulgaris in the Bulgarian population.Frontiers in immunology · 2022Article
- Researching trends in pemphigoid diseases: A bibliometric study of the top 100 most cited publications.Frontiers in medicine · 2022Article
- Bullous pemphigoid caused by contact allergy to bone cement: A case report.Contact dermatitis · 2021Article
- Detection of autoreactive CD4+ T cells by MHC class II multimers in HLA-linked human autoimmune diseases.The Journal of clinical investigation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune bullous disorders are a group of severe skin diseases characterized clinically by blisters and erosions of skin and/or mucous membranes. A hallmark of these disorders is the presence of IgG and occasionally IgA autoantibodies that target distinct adhesion structures of the epidermis, dermoepidermal basement membrane, and anchoring fibrils of the dermis. This Review focuses on the potential role of autoreactive T cells in the pathogenesis of these disorders. Pemphigus vulgaris (PV) and bullous pemphigoid (BP) are the best-characterized bullous disorders with regard to pathogenesis and T cell involvement. Activation of autoreactive T cells in PV and BP is restricted by distinct HLA class II alleles that are prevalent in individuals with these disorders. Autoreactive T cells are not only present in patients but can also be detected in healthy individuals. Recently, a subset of autoreactive T cells with remarkable regulatory function was identified in healthy individuals and to a much lesser extent in patients with PV, suggesting that the occurrence of autoimmune bullous disorders may be linked to a dysfunction of Tregs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.